Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2016-12-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well combination chemotherapy and pralatrexate works in
treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing
Phase:
Phase 2
Details
Lead Sponsor:
University of Nebraska
Collaborators:
National Cancer Institute (NCI) Spectrum Pharmaceuticals, Inc